{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-053529","form_type":"8-K","ticker":"QTRX","cik":"0001503274","company_name":"Quanterix Corp","filed_at":"2022-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.947323+00:00","generated_at":"2026-06-26T02:34:31.731657+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Quanterix names Masoud Toloue CEO, Hrusovsky Executive Chairman","bullets":["Masoud Toloue appointed CEO and elected to the Board effective April 25, 2022.","Toloue's base salary $550k; target bonus up to 100%; $2M equity grant (70% options/30% RSUs) vesting over 4 years.","E. Kevin Hrusovsky transitions from CEO to Executive Chairman through Dec 31, 2022; base $400k; $1.4M equity grant with continued vesting.","Succession was previously announced on March 1, 2022; this filing formalizes the changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-053529","json":"https://secwatch.observer/filing/0001104659-22-053529.json","markdown":"https://secwatch.observer/filing/0001104659-22-053529.md","text":"https://secwatch.observer/filing/0001104659-22-053529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503274/000110465922053529/0001104659-22-053529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503274/000110465922053529/tm2213874d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T02:34:31.731657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c4ca14d195","claim":"Masoud Toloue was appointed as Class II director at Quanterix Corp.","evidence_excerpt":"Effective April 25, 2022, Dr. Toloue was also appointed to serve on the Company’s Board as a Class II director, with a term ending at the 2022 annual meeting of stockholders, and will continue to serve as the Company’s President.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503274/000110465922053529/0001104659-22-053529-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"},{"claim_id":"ce23ff800b","claim":"Masoud Toloue was appointed as Chief Executive Officer at Quanterix Corp.","evidence_excerpt":"Effective April 25, 2022, Masoud Toloue, Ph.D., President of Quanterix and Diagnostics, was appointed Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503274/000110465922053529/0001104659-22-053529-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"dfb6308b7d","claim":"E. Kevin Hrusovsky changed role as Executive Chairman at Quanterix Corp.","evidence_excerpt":"E. Kevin Hrusovsky has transitioned from his role as Chief Executive Officer and was appointed Executive Chairman of the Company’s Board of Directors (the “Board”), effective April 25, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503274/000110465922053529/0001104659-22-053529-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}